Prior treatments influence immunotherapy response in advanced melanoma

April 24, 2023
Findings may help scientists create more precise future treatments and predict which patients will benefit most from current immune checkpoint blockade.

Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.

Their findings, based on analysis of seven data sets generated over the past decade, which included results of tumor biopsies from more than 500 patients, are published in Cancer Cell.

UCLA release